Science

Endeavor

to Treat Severe Health Conditions

Our Precision Medicine Approach

Patients require precision treatments that focus on the core drivers of their disease. With technological advancements like commercial next-generation sequencing and enhanced molecular profiling, this approach is now realized. We can uncover the drivers of various diseases, and therefore the medicines that can safely target them and improve patient lives.

Oncology

We are pursuing a number of different precision medicine approaches and targets in oncology

Hedgehog Signaling Inhibition

The Hedgehog signaling pathway plays a key role during embryonic development, wound healing, oncology and fibrosis. Mutations in this pathway are an underlying driver of 2% of all cancers. Because of its prevalence across oncology and its ability to aberrantly activate downstream signaling, there is the potential to utilize Hedgehog inhibitors for tumor-agnostic indications.

We are investigating our product candidate, ENV-101, in multiple types of cancer where Hedgehog pathway is implicated in tumor formation.

ULK1/2 and Autophagy Inhibition

Autophagy is a process that fuels cancer cells and requires ULK1/2 for activation. Tumors bearing mutations in RAS and LKB1 (STK11) are more sensitive to blockade autophagy. We are developing a precision medicine, ENV-201, that targets ULK1/2 and thereby arrests autophagy for the treatment of cancer.

For more information on ENV-101 and ENV-201, please visit our Pipeline page.

Idiopathic Pulmonary Fibrosis (IPF)

Hedgehog signaling is a driver of IPF: a progressive, irreversible, and fatal disease that causes tissue remodeling and scarring of the lungs.

Hedgehog Signaling Inhibition

Myofibroblasts are repair cells generated by the Hedgehog pathway— they become dysregulated in IPF, relentlessly remodeling lung tissue, forming fibrotic scar tissue, and contracting the lung. With approximately 132,000 people affected by IPF in the U.S. alone, there is a significant unmet need in this patient community, with people only surviving two to three years after initial diagnosis.

We are currently investigating ENV-101 in patients with IPF. For more information on this program, please visit our Pipeline page.

Publications and Presentations

  • Author, A. A., Author B. B., & Author, C. C. (Year).

    Title of Journal, Volume(Issue), pages–pages. https://doi.org/XXXXXXXXXXX

  • Author, A. A., Author B. B., & Author, C. C. (Year).

    Title of Journal, Volume(Issue), pages–pages. https://doi.org/XXXXXXXXXXX

  • Author, A. A., Author B. B., & Author, C. C. (Year).

    Title of Journal, Volume(Issue), pages–pages. https://doi.org/XXXXXXXXXXX

  • Author, A. A., Author B. B., & Author, C. C. (Year).

    Title of Journal, Volume(Issue), pages–pages. https://doi.org/XXXXXXXXXXX